TrialSpark, a tech-enabled drug development partner involved in improving the speed, quality and innovation of clinical trials, announced yesterday that it has named and Dr Ken Somberg as its new chief medical officer and Quentin Chu as its new president and chief financial officer.
After spending 12 years at Novartis where he served as the therapeutic area head for Clinical Research, and later in Regulatory Affairs for the Transplantation and Immunology Business Unit, Somberg joined Covance Inc as CMO in 2009. Most recently, Somberg served as CMO of Nevakar Inc, focusing on developing innovative products in injectable and ophthalmic therapeutics.
Prior to joining TrialSpark, Chu was CFO at CityMD, with experience in healthcare and private equity having served at Crestview Partners and The Carlyle Group.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic